Shots:

• Artios to receive $30M up front & near-term milestones- ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally- Artios has opt-in rights for joint development & commercialization of the programs
• Merck has the right to opt into exclusive development & commercialization of compounds on up to 8 targets
• The collaboration leverages Artios’ nuclease targeting discovery platform to jointly identify multiple synthetic lethal targets for precision oncology drug candidates while Merck KGaA will utilize its expertise and resources in the field of DDR

­ Ref: PRNewswire | Image: Merck KGaA